Back to top
more

Mirum Pharmaceuticals (MIRM)

(Real Time Quote from BATS)

$53.67 USD

53.67
256,482

+1.83 (3.53%)

Updated Aug 6, 2025 02:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Mirum Gains 35% in 3 Months: How Should You Play the Stock?

by Zacks Equity Research

MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.

Zacks Equity Research

EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch

by Zacks Equity Research

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

Zacks Equity Research

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch

by Zacks Equity Research

GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.

Zacks Equity Research

Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised

by Zacks Equity Research

MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of 23.08% and 13.32%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of 3.55% and 26.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?

by Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe

by Zacks Equity Research

MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.

Zacks Equity Research

MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

by Zacks Equity Research

Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -81.48% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Mirum Pharmaceuticals (MIRM) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

SANA Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Sana Biotechnology's Q4 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.

Zacks Equity Research

SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know

by Zacks Equity Research

Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.

Zacks Equity Research

CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know

by Zacks Equity Research

Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.

Zacks Equity Research

What's in the Cards for Viatris Stock This Q4 Earnings?

by Zacks Equity Research

VTRS' Q4 results are likely to gain from new product launches in all major geographies.

Zacks Equity Research

Cassava Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

Zacks Equity Research

ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Zacks Equity Research

Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.